Financial releases

Crossject achieves key ZEPIZURE® manufacturing milestone

Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference

Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America

Crossject announces highly successful closing of its €8 million rights offering

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe

Crossject announces a rights issue for approximately €8 million to support the registration of ZEPIZURE® and its continued expansion in the U.S.

Crossject reports audited financial results for 2023